Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CASP1 | P29466 | 3/20 | 0.39 |
| ▸ | CASP7 | P55210 | 3/20 | 0.39 |
| ▸ | HBB | P68871 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15880793 | 0.98 | ALDH1A1 (0.41) | ALDH1A1MAPTSMN1; SMN2RAB9AHPGD | |
| SCHEMBL28457906 | 0.84 | MAPT (0.39) | ALDH1A1MAPTSMN1; SMN2RAB9AHPGD | |
| SCHEMBL760406 | 0.81 | CYP2A6 (0.55) | ALDH1A1MAPTRAB9ACA2DYRK1A | |
| Hydrochloric Acid SCHEMBL10370258 | 0.79 | CYP2A6 (0.53) | ALDH1A1MAPTRAB9ACA2DYRK1A | |
| Ethoxycarbonyl Group SCHEMBL28477301 | 0.79 | CYP2A6 (0.35) | ALDH1A1MAPTSMN1; SMN2HPGDCA2 | |
| SCHEMBL13742552 | 0.75 | DYRK1A (0.48) | CA2DYRK1ACYP2A6SLC6A2SLC6A4 | |
| SCHEMBL164774 | 0.73 | CYP2A6 (0.50) | ALDH1A1SMN1; SMN2RAB9ACA2DYRK1A | |
| SCHEMBL12569411 | 0.73 | CYP2A6 (0.52) | ALDH1A1MAPTHSD17B10CYP2A6HIF1A | |
| SCHEMBL422225 | 0.71 | CYP2A6 (0.48) | MAPTRAB9ACA2CYP2A6TDP1 | |
| SCHEMBL18725843 | 0.71 | CYP2A6 (0.36) | DYRK1ACYP2A6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269819-B2 | Small molecule inhibitors of Galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20230165885-A1 | TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES | GLIAGUARD, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023068852-A1 | BENZOTHIOPHENE-1,1-DIOXIDE DERIVATIVE COMPOUND AS STAT3 INHIBITOR, AND USE THEREOF | 주식회사 프롬바이오 | 2023-04-27 | — | — | WO | disclosed |
| US-20220185800-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220144818-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3953349-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210308-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210308-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| WO-2006115833-A1 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES WITH CARBAMATE, UREA, AMIDE AND SULFONAMIDE SUBSTITUTIONS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1677731-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | Aton Pharma, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2005034880-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-6207701-B1 | AS ANTI-ANGIOGENIC, ANTI-ARTHRITIC, ANTI-INFLAMMATORY, ANTI-RETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC AGENTS | ABBOTT LABORATORIES | 2001-03-27 | — | — | US | disclosed |
| WO-2000063202-A2 | BENZO[b] THIOPHENE SULFONAMIDE-1, 1-DIOXIDE DERIVATIVES AND THEIR USE AS ANTINEOPLASTIC AGENTS | UNIVERSIDAD PUBLICA DE NAVARRA (ES) | 2000-10-26 | — | — | WO | disclosed |
| US-4695571-A | Tricyclic oxindole antiinflammatory agents | PFIZER INC. (US) | 1987-09-22 | — | — | US | disclosed |
| WO-1986001510-A1 | TRICYCLIC OXINDOLE ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1986-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185800-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | ALDH1A1 2839/4885MAPT 3064/4885SMN1; SMN2 4130/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ALDH1A1 2165/4885MAPT 4269/4885SMN1; SMN2 4837/4885 |
| US-20220144818-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS3BP, LGALS1 | ALDH1A1 3232/4885MAPT 2876/4885SMN1; SMN2 4169/4885 |
| US-20230165885-A1 | TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES | P2RY6, P2RY1, P2RY2 | ALDH1A1 1347/4885MAPT 627/4885SMN1; SMN2 2615/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | ALDH1A1 2221/4885MAPT 4847/4885SMN1; SMN2 4740/4885 |
| US-12269819-B2 | Small molecule inhibitors of Galectin-3 | LGALS3, LGALS3BP, LGALS1 | ALDH1A1 3232/4885MAPT 2876/4885SMN1; SMN2 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.